RESEARCH SUPPORT, NON-U.S. GOV'T
Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-igd and periodic fever syndrome: its application as a diagnostic tool.
Annals of Internal Medicine 2001 September 5
BACKGROUND: The hyper-IgD and periodic fever syndrome (HIDS) is characterized by recurrent attacks of fever, abdominal distress, and arthralgia and is caused by mevalonate kinase mutations.
OBJECTIVE: To ascertain the role of mevalonate kinase and the usefulness of molecular diagnosis in HIDS.
DESIGN: Cross-sectional study.
SETTING: The international Nijmegen HIDS registry.
PATIENTS: 54 patients from 41 families who met the clinical criteria for HIDS.
MEASUREMENTS: Clinical symptoms and signs, immunoglobulin concentration, leukocyte count, erythrocyte sedimentation rate, mutation analysis, and mevalonate kinase enzyme activity assay.
RESULTS: There were two groups of patients: 41 patients with mevalonate kinase mutations (classic-type HIDS) and 13 patients without mutations (variant-type HIDS). Patients with classic-type HIDS had a lower mevalonate kinase enzyme activity, a higher IgD level, and more additional symptoms with attacks. The IgD level did not correlate with disease severity, mevalonate kinase enzyme activity, or genotype.
CONCLUSION: Genetic heterogeneity exists among patients with a clinical diagnosis of HIDS.
OBJECTIVE: To ascertain the role of mevalonate kinase and the usefulness of molecular diagnosis in HIDS.
DESIGN: Cross-sectional study.
SETTING: The international Nijmegen HIDS registry.
PATIENTS: 54 patients from 41 families who met the clinical criteria for HIDS.
MEASUREMENTS: Clinical symptoms and signs, immunoglobulin concentration, leukocyte count, erythrocyte sedimentation rate, mutation analysis, and mevalonate kinase enzyme activity assay.
RESULTS: There were two groups of patients: 41 patients with mevalonate kinase mutations (classic-type HIDS) and 13 patients without mutations (variant-type HIDS). Patients with classic-type HIDS had a lower mevalonate kinase enzyme activity, a higher IgD level, and more additional symptoms with attacks. The IgD level did not correlate with disease severity, mevalonate kinase enzyme activity, or genotype.
CONCLUSION: Genetic heterogeneity exists among patients with a clinical diagnosis of HIDS.
Full text links
Trending Papers
Management of Hyponatremia in Heart Failure: Practical Considerations.Journal of Personalized Medicine 2023 January 11
Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment.Frontiers in Immunology 2022
Management of heart failure in patients with kidney disease - updates from the 2021 ESC guidelines.Nephrology, Dialysis, Transplantation 2023 January 24
2023 American Society of Anesthesiologists Practice Guidelines for Preoperative Fasting: Carbohydrate-containing Clear Liquids with or without Protein, Chewing Gum, and Pediatric Fasting Duration-A Modular Update of the 2017 American Society of Anesthesiologists Practice Guidelines for Preoperative Fasting.Anesthesiology 2023 Februrary 2
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app